In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers

Movement Disorders

Volumn 29, Issue 9, 2014, Pages 1197-1201

  Felicio, Andre C ^a   Dinelle, Katherine ^a   Agarwal, Pankaj A ^a   Mckenzie, Jessamyn ^a   Heffernan, Nicole ^a   Road, Jeremy D ^a   Appel Cresswell, Silke ^a   Wszolek, Zbigniew K ^b   Farrer, Matthew J ^a   Schulzer, Michael ^a   Sossi, Vesna ^a   Stoessl, A Jon ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

Dopaminergic dysfunction; Dynactin gene; Perry syndrome; Positron emission tomography; Serotonergic dysfunction

Indexed keywords

3-AMINO-4-(2-DIMETHYLAMINOMETHYLPHENYLSULFANYL)BENZONITRILE; ANILINE DERIVATIVE; DIHYDROTETRABENAZINE; DOPAMINE; DYNACTIN; FLUORINE; MICROTUBULE ASSOCIATED PROTEIN; RACLOPRIDE; SEROTONIN; SULFIDE; TETRABENAZINE;

ADULT; ANALOGS AND DERIVATIVES; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORPUS STRIATUM; DEPRESSION; DIAGNOSTIC USE; GENETICS; HUMAN; HYPOVENTILATION; METABOLISM; MIDDLE AGED; MUTATION; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

ADULT; ANILINE COMPOUNDS; CORPUS STRIATUM; DEPRESSION; DOPAMINE; FLUORINE RADIOISOTOPES; HUMANS; HYPOVENTILATION; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MUTATION; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; RACLOPRIDE; SEROTONIN; SULFIDES; TETRABENAZINE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84906064821     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25893     Document Type: Article

References (10)

1. Farrer MJ, Hulihan MM, Kachergus JM, et al. DCTN1 mutations in Perry syndrome. Nat Genet 2009;41:163-165.
2. Perry TL, Wright JM, Berry K, Hansen S, Perry TL Jr. Dominantly inherited apathy, central hypoventilation, and Parkinson's syndrome: clinical, biochemical, and neuropathologic studies of 2 new cases. Neurology 1990;40:1882-1887.
3. Lechevalier B, Chapon F, Defer G, et al. Perry and Purdy's syndrome (familial and fatal parkinsonism with hypoventilation and athymhormia). Bull Acad Natl Med 2005;189:481-490.
4. Nandhagopal R, Kuramoto L, Schlzer M, et al. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. Brain 2011;134:3290-3298.
5. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-764.
6. Kaasinen V, Ruottinen HM, Någren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med 2000;41:65-70.
7. Doudet DJ, Jivan S, Ruth TJ, Holden JE. Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride. Synapse 2002;44:198-202.
8. Boileau I, Warsh JJ, Guttman M, et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord 2008;23:1776-1780.
9. Wider C, Dickson DW, Stoessl AJ, et al. Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord 2009;15:281-286.
10. Tsuboi Y, Dickson DW, Nabeshima K, et al. Neurodegeneration involving putative respiratory neurons in Perry syndrome. Acta Neuropathol 2008;115:263-268.